Sangamo Therapeutics in Chapter 11 reports $23.2M cash and $107.3M liabilities
Sangamo Therapeutics filed its monthly Chapter 11 operating report covering August 2026, showing month-end cash and total liabilities.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Sangamo Therapeutics has filed its monthly operating report in its Chapter 11 bankruptcy case. According to the filing, cash stood at $23,225,696 at the end of August 2026, while total liabilities reached $107,262,249. The report covers August 1 to 31, 2026, and was filed in Case No. 26-10989 in the Delaware Bankruptcy Court.
Cash rose from $16,906,954 as receipts of $10,145,433 outpaced disbursements of $3,826,691. Total assets were reported at $147,881,705, leaving ending equity of $40,619,456. The company also drew an additional $7.0 million in DIP borrowings during August. Equipment sales included $2.3 million to Surplus Solutions and a $250,000 sale to FSI, which was offset against DIP obligations.
why it matters
For the broader market this is a routine bankruptcy filing rather than a sector-wide event. The figures show Sangamo relying on DIP financing and asset sales, while equity remains positive. Investors should weigh the risk of further restructuring.
market impact
Sangamo shares: the report underscores financial strain and reliance on borrowed funding
tags
instruments
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗